Edgar Filing: LEWIS JOEL - Form 4

LEWIS JOEI											
Form 4	2017										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										PPROVAL 3235-0287	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							Expires: Estimated a burden hou response n	rs per			
(Print or Type R	esponses)										
1. Name and Address of Reporting Person <u>*</u> LEWIS JOEL			2. Issuer Name and Ticker or Trading Symbol GALECTIN THERAPEUTICS INC [GALT]				-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 3. Date o				of Earliest Transaction Day/Year) 2017				XDirector10% Owner Officer (give titleOther (specify below) below)			
(Street) 4. If Amer				endment, Date Original nth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Tabl	L Non D	arivativa S	oouri	tios A ca	Person uired, Disposed of	f or Bonoficial	ly Ownod	
1.Title of Security (Instr. 3)	2. Transaction E (Month/Day/Yea	ar) Executio any	med	3. Transactic Code (Instr. 8)	4. Securit	ies Ac sposed	quired of (D)	5. Amount of	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of	
Common Stock	12/14/2017			А	23,013 (1)	А	\$ 2.39	50,880	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: LEWIS JOEL - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	\$ 2.39	12/14/2017		А	62,250	(2)	12/14/2027	Common stock	62,250

Reporting Owners

Reporting Owner Name / Address			Relationships					
The Portuge of March 1990 (1990)	Director	10% Owner	Officer	Other				
LEWIS JOEL C/O GALECTIN THERAPEUTICS, INC. 4960 PEACHTREE INDUSTRIAL BLVD., NORCROSS, GA 30071	STE 240	X						
Signatures								
Jack W. Callicutt, by power of attorney	12/18/2017	7						

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These restricted shares were issued in lieu of cash retainer and meeting fees of \$55,000 for 2018. Restrictions on the shares lapse at a rate of 25% per calendar quarter in 2018.
- (2) The options vest 100% on December 14, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

8 E S ()